Literature DB >> 28166863

Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study.

S M Nielsen1, N G Toftdahl1, M Nordentoft1, C Hjorthøj1.   

Abstract

BACKGROUND: Several studies have examined whether use of substances can cause schizophrenia. However, due to methodological limitations in the existing literature (e.g. selection bias and lack of adjustment of co-abuse) uncertainties still remain. We aimed to investigate whether substance abuse increases the risk of developing schizophrenia, addressing some of these limitations.
METHOD: The longitudinal, nationwide Danish registers were linked to establish a cohort of 3 133 968 individuals (105 178 673 person-years at risk), identifying 204 505 individuals diagnosed with substance abuse and 21 305 diagnosed with schizophrenia. Information regarding substance abuse was extracted from several registers and did not include psychotic symptoms caused by substance abuse in the definition. This resulted in a large, generalizable sample of exposed individuals. The data was analysed using Cox regression analyses, and adjusted for calendar year, gender, urbanicity, co-abuse, other psychiatric diagnosis, parental substance abuse, psychiatric history, immigration and socioeconomic status.
RESULTS: A diagnosis of substance abuse increased the overall risk of developing schizophrenia [hazard ratio (HR) 6.04, 95% confidence interval (CI) 5.84-6.26]. Cannabis (HR 5.20, 95% CI 4.86-5.57) and alcohol (HR 3.38, 95% CI 3.24-3.53) presented the strongest associations. Abuse of hallucinogens (HR 1.86, 95% CI 1.43-2.41), sedatives (HR 1.68, 95% CI 1.49-1.90), and other substances (HR 2.85, 95% CI 2.58-3.15) also increased the risk significantly. The risk was found to be significant even 10-15 years subsequent to a diagnosis of substance abuse.
CONCLUSION: Our results illustrate robust associations between almost any type of substance abuse and an increased risk of developing schizophrenia later in life.

Entities:  

Keywords:  Alcohol; cannabis; schizophrenia; substance use disorders

Mesh:

Year:  2017        PMID: 28166863     DOI: 10.1017/S0033291717000162

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  14 in total

1.  Impulsivity in unaffected adolescent biological relatives of schizophrenia patients.

Authors:  Beng-Choon Ho; Amy B Barry; Julie A Koeppel
Journal:  J Psychiatr Res       Date:  2017-11-21       Impact factor: 4.791

Review 2.  Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.

Authors:  Asma Khan; Susan B Powell
Journal:  Schizophr Res       Date:  2017-10-22       Impact factor: 4.939

3.  Marijuana Legalization Will Cause Many Problems for Missouri Law Enforcement and Schools.

Authors:  David G Evans
Journal:  Mo Med       Date:  2019 May-Jun

4.  Association of Substance Use Disorders With Conversion From Schizotypal Disorder to Schizophrenia.

Authors:  Carsten Hjorthøj; Nikolai Albert; Merete Nordentoft
Journal:  JAMA Psychiatry       Date:  2018-07-01       Impact factor: 21.596

Review 5.  Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells.

Authors:  Samuel K Powell; Callan P O'Shea; Sara Rose Shannon; Schahram Akbarian; Kristen J Brennand
Journal:  Adv Neurobiol       Date:  2020

6.  Outpatient prescribing of opioids to adults diagnosed with mental disorders in the United States.

Authors:  Matthew T Taylor; Daniel B Horton; Theresa Juliano; Mark Olfson; Tobias Gerhard
Journal:  Drug Alcohol Depend       Date:  2020-11-23       Impact factor: 4.492

7.  New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders.

Authors:  Evangelos Evangelou; He Gao; Congying Chu; Georgios Ntritsos; Jimmy D Bell; Paul M Matthews; Adrian Rothenfluh; Sylvane Desrivières; Gunter Schumann; Paul Elliott; Paul Blakeley; Andrew R Butts; Raha Pazoki; Hideaki Suzuki; Fotios Koskeridis; Andrianos M Yiorkas; Ibrahim Karaman; Joshua Elliott; Qiang Luo; Stefanie Aeschbacher; Traci M Bartz; Sebastian E Baumeister; Peter S Braund; Michael R Brown; Jennifer A Brody; Toni-Kim Clarke; Niki Dimou; Jessica D Faul; Georg Homuth; Anne U Jackson; Katherine A Kentistou; Peter K Joshi; Rozenn N Lemaitre; Penelope A Lind; Leo-Pekka Lyytikäinen; Massimo Mangino; Yuri Milaneschi; Christopher P Nelson; Ilja M Nolte; Mia-Maria Perälä; Ozren Polasek; David Porteous; Scott M Ratliff; Jennifer A Smith; Alena Stančáková; Alexander Teumer; Samuli Tuominen; Sébastien Thériault; Jagadish Vangipurapu; John B Whitfield; Alexis Wood; Jie Yao; Bing Yu; Wei Zhao; Dan E Arking; Juha Auvinen; Chunyu Liu; Minna Männikkö; Lorenz Risch; Jerome I Rotter; Harold Snieder; Juha Veijola; Alexandra I Blakemore; Michael Boehnke; Harry Campbell; David Conen; Johan G Eriksson; Hans J Grabe; Xiuqing Guo; Pim van der Harst; Catharina A Hartman; Caroline Hayward; Andrew C Heath; Marjo-Riitta Jarvelin; Mika Kähönen; Sharon L R Kardia; Michael Kühne; Johanna Kuusisto; Markku Laakso; Jari Lahti; Terho Lehtimäki; Andrew M McIntosh; Karen L Mohlke; Alanna C Morrison; Nicholas G Martin; Albertine J Oldehinkel; Brenda W J H Penninx; Bruce M Psaty; Olli T Raitakari; Igor Rudan; Nilesh J Samani; Laura J Scott; Tim D Spector; Niek Verweij; David R Weir; James F Wilson; Daniel Levy; Ioanna Tzoulaki
Journal:  Nat Hum Behav       Date:  2019-07-29

Review 8.  Women who suffer from schizophrenia: Critical issues.

Authors:  Mary V Seeman
Journal:  World J Psychiatry       Date:  2018-11-09

9.  Ethics and ego dissolution: the case of psilocybin.

Authors:  William R Smith; Dominic Sisti
Journal:  J Med Ethics       Date:  2020-05-27       Impact factor: 5.926

Review 10.  [Addictive behaviors: Clinical facts].

Authors:  C Lucet; J P Olié
Journal:  Bull Acad Natl Med       Date:  2020-04-15       Impact factor: 0.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.